All posts by Iain Wilkie
Research Analyst
Sectors Covered: Healthcare and Life Sciences
By Iain Wilkie
18 August 2022, 4:00 PM
Pro Medicus (ASX:PME) recorded another year of strong growth across all metrics with the key highlight being further EBIT margin expansion to 67% well above expectations, highlighting the operating leverage of the business.
Read more...
By Iain Wilkie
17 June 2022, 9:00 AM
Since our last report (17 March), the losses across our basket of 185 ASX listed healthcare stocks have continued to accelerate, with an average loss of 23.5%.
Read more...
By Iain Wilkie
17 March 2022, 11:00 AM
We have compiled a list of 75 ASX-listed micro to mid-cap healthcare/life science companies and highlight key catalysts expected to read out over the next 18 months.
Read more...
By Iain Wilkie
08 March 2022, 12:00 PM
The US Patent Office (USTPO) has issued a final rejection notice for Paradigm Biopharmaceuticals' (ASX:PAR) key osteoarthritis patent application.
Read more...
By Iain Wilkie
17 February 2022, 11:00 AM
Pro Medicus (ASX:PME) delivered a strong result with NPAT up 52.7% to A$20.7m, above our forecasts and consensus.
Read more...
By Iain Wilkie
05 January 2022, 10:30 AM
We update our recommendation for Pro Medicus (ASX:PME) based on recent share price strength, which we view has run ahead of fair value in the short term.
Read more...
By Iain Wilkie
01 October 2021, 8:30 AM
Pro Medicus (ASX:PME) has announced the signing of US-based Novant Health on a 7-year A$40m contract for the workflow and viewer products.
Read more...
By Iain Wilkie
19 August 2021, 10:00 AM
Pro Medicus (ASX:PME) recorded another year of strong growth across all metrics although lower than our forecasts and consensus expectations.
Read more...
By Iain Wilkie
30 March 2021, 4:00 PM
Morgans analyst Iain Wilkie speaks with Chief Executive Officer and Managing Director of ResApp (ASX:RAP), Tony Keating. Tony provides an update on a number of recent news events.
Read more...
By Iain Wilkie
17 November 2020, 11:00 AM
Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.
Read more...